1. Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post- Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High- Risk Hematologic Malignancies 
Orly R. Klein, Jessica Buddenbaum, Noah Tucker, Allen R. Chen, Christopher J. Gamper, David Loeb, Elias Zambidis, Nicolas J. Llosa, Jeffrey S. Huo, Nancy Robey, Mary Jo Holuba, Yvette L. Kasamon, Shannon R. McCurdy, Richard Ambinder, Javier Bolaños-Meade, Leo Luznik, Ephraim J. Fuchs, Richard J. Jones, Kenneth R. Cooke, Heather J. Symons 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 2, Pages (February 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Preparative regimen and graft-versus-host disease prophylaxis. Fludarabine 30 mg/m2 i.v. days −6 through −2, cyclophosphamide (Cy) 14.5 mg/kg i.v. days −6 and −5, total body irradiation 200 cGy day −1, graft infusion day 0, Cy 50 mg/kg/dose i.v. days +3 and +4, mycophenolate mofetil (MMF) 15 mg/kg/dose per oral 3 times daily (maximum daily dose 3 gm/day) days +5 through +35, tacrolimus .015 mg/kg/dose i.v. every 12 hours day +5 through either day +60, +90, or day +180, and filgrastim 5 µg/kg/day day +5 through neutrophil recovery.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) Cumulative incidences of grades 2 to 4 and grades 3 to 4 acute GVHD. (B) Cumulative incidence of overall chronic GVHD and moderate-severe GVHD. (C) Cumulative incidence of relapse. (D) Cumulative incidence of transplantation-related mortality.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Cumulative incidences of overall survival and event-free survival.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
Cumulative incidence of overall survival, analyzed by subgroups. (A) Age at the time of BMT; (B), prior myeloablative alloBMT; (C), year of BMT; (D), MRD status; (E), met eligibility for myeloablation.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions